Introduction
============

Pharmacotherapy for cancer pain is based on the World Health Organization (WHO) guidelines for cancer-pain relief released in 1986.[@b1-jpr-10-1953] The WHO's three-step ladder for cancer-pain relief recommends the use of potent opioid analgesics for moderate--severe pain; indeed, these agents have been found to be the most effective treatment for cancer pain.[@b2-jpr-10-1953] At present, morphine, oxycodone, and fentanyl are mainly used in Japan as step 3 opioid analgesics.

The selective μ-opioid receptor-agonist analgesic hydromorphone is currently used clinically in 45 countries and regions in the world.[@b3-jpr-10-1953] It is the standard alternative to morphine,[@b4-jpr-10-1953]--[@b7-jpr-10-1953] but has not been developed for use in Japan. The metabolites of hydromorphone have been found to be inactive,[@b8-jpr-10-1953] making hydromorphone a potential treatment option for patients with reduced renal function as an alternative to morphine.[@b9-jpr-10-1953],[@b10-jpr-10-1953] Therefore, hydromorphone is expected to expand the treatment options for pain relief.

The efficacy and safety of hydromorphone has been assessed in clinical studies.[@b11-jpr-10-1953] During the development of hydromorphone in Japan, Daiichi Sankyo made a once-daily extended-release formulation.[@b12-jpr-10-1953],[@b13-jpr-10-1953] We conducted a Phase III randomized double-blind study to verify the noninferiority of hydromorphone extended-release tablets (DS-7113b; Daiichi Sankyo, Tokyo, Japan) to oxycodone hydrochloride extended-release tablets (Oxycontin; Shionogi, Osaka, Japan), with the objective of investigating the efficacy of the hydromorphone formulation in Japanese patients.

Subjects and methods
====================

This study was conducted from 2014 to 2015 as a multicenter, active-controlled, randomized, double-blind, parallel-group comparison study, enrolling 184 patients at 49 institutions. The institutes participating in the study are listed in [Box S1](#SD1-jpr-10-1953){ref-type="supplementary-material"}. The study was approved by the institutional review board of each study site and carried out in compliance with ethical principles based on the Declaration of Helsinki and Good Clinical Practice. Written informed consent was obtained from all subjects prior to study participation. The registered clinical trial number: JapicCTI-142666.

Participants
------------

The study participants were cancer patients aged 20 years and older receiving nonopioid analgesics for cancer pain who had not used opioid analgesics within 2 weeks prior to enrollment. At enrollment, visual analog scale (VAS) score (average pain within the last 24 hours) was required to be ≥35 mm (moderate--severe pain that interferes with functioning),[@b14-jpr-10-1953]--[@b16-jpr-10-1953] with an Eastern Cooperative Oncology Group performance status ≤3. All patients were judged by the investigator to require treatment with potent opioid analgesics. Patients presenting with symptoms for which oxycodone or morphine are contraindicated or relatively contraindicated, those receiving a monoamine oxidase inhibitor within 14 days prior to enrollment, those participating in another clinical trial within 28 days prior to enrollment, and those with serious hepatic, renal, or respiratory disorder of Common Terminology Criteria for Adverse Events grade 3 were excluded.

Study design
------------

Subjects were randomized at a ratio of 1:1 to either the hydromorphone group or the oxycodone group. A double-dummy method was used for blinding, and each randomized subject received either hydromorphone extended-release tablets plus placebo oxycodone hydrochloride extended-release tablets or placebo hydromorphone extended-release tablets plus oxycodone hydrochloride extended-release tablets orally for 7 days (once-daily dosing for hydromorphone and twice-daily dosing for oxycodone). The initial dose was 4 mg/day of hydromorphone extended-release tablets and 10 mg/day of oxycodone hydrochloride extended-release tablets. Investigators were allowed to increase the doses of the study drugs every 24 hours during the treatment period if necessary due to insufficient analgesic efficacy. Doses could be increased in five stages up to a maximum of 24 mg/day of hydromorphone and 80 mg/day of oxycodone ([Table 1](#t1-jpr-10-1953){ref-type="table"}). Treatment was switched to appropriate analgesics after completion of study treatment, and subjects were followed up. The initial dose of hydromorphone extended-release tablets was determined as 4 mg/day, which was assumed to be equivalent to 20 mg/day of morphine on the basis of the fivefold-higher efficacy ratio of hydromorphone compared with morphine (Exalgo; Mallinckrodt Brand Pharmaceuticals, Hazelwood, MO, USA). The initial dose of oxycodone hydrochloride extended-release tablets was determined as 10 mg/day, which is specified as the dose for opioid-naïve patients in the Japanese package insert.

From the start of study treatment to the completion (or discontinuation) of treatment, each subject evaluated their average pain severity once daily for the last 24 hours using the VAS and recorded the score in the patient diary. Oral morphine hydrochloride solution was used for rescue analgesia to avoid using the investigational agents for rescue ([Table 1](#t1-jpr-10-1953){ref-type="table"}). The immediate-release preparations of hydromorphone and oxycodone faced challenges of being unapproved and potential confounding of safety assessments, respectively.

Concomitant use of monoamine oxidase inhibitors, opioid analgesics, and narcotic antagonists was prohibited. In addition, starting new treatment with/changing the dosing regimen of systemic nonopioid analgesics, adjuvant analgesics for pain relief, bisphosphonates, or anti-RANKL antibody preparations was prohibited. Furthermore, it was prohibited for subjects to undergo radiotherapy, nerve block, percutaneous vertebroplasty, or surgery, or receive any new cancer chemotherapy or immunotherapy for the first time. Magnesium oxide at 2 g/day and prochlorperazine maleate at 15 mg/day were administered to all subjects to ensure balanced evaluation of constipation and nausea/vomiting.

Outcomes
--------

The primary efficacy end point was the change in VAS score from baseline to completion or discontinuation of treatment. Secondary end points evaluated were change in VAS score and sleep quality from baseline to each evaluation day. Sleep quality was assessed using a 4-point rating scale. The safety population included all subjects who were randomized to receive at least one dose of either treatment option. Adverse events (AEs) were recorded throughout the study period. AEs could be determined by investigators during examination or could be reported voluntarily by patients. Incidence, intensity, and relationship to the study drug were reported for AEs. Serious AEs, including death, were reported for both treatment arms, and attribution to treatment was determined. Clinical and laboratory assessments were performed at periodic intervals (day 1, day 8, and discontinuation) throughout the study period. Investigators coded the AEs by system organ class and preferred terms based on the MedDRA (Medical Dictionary for Regulatory Activities, version 18.1; <http://www.meddra.org>). Severity of AEs was rated on a three-grade scale (mild, moderate, and severe).

Statistical analysis
--------------------

The full-analysis set (FAS) consisted of all patients with at least one measurement of the primary-efficacy parameter, at least one dose of study medication, and no serious Good Clinical Practice violation, and was the primary analysis population for efficacy. The level of significance used for the hypothesis test was 5% (two-sided), and the CI was 95% (two-sided). SAS 9.2 (SAS Inc, Cary, NC, USA) was used for statistical analysis. Summary statistics were calculated for VAS scores at baseline, at the completion or discontinuation of treatment, and for changes in VAS score. For primary efficacy evaluation, analysis of covariance was performed using baseline VAS score as a covariate to calculate the two-sided 95% CI for the difference in the hydromorphone and oxycodone groups (hydromorphone group -- oxycodone group) in least squares mean changes in VAS score, in order to ensure that the upper limit did not exceed 10 mm, which was defined as the noninferiority limit. *P*-values and least squares means for paired comparisons for each group were calculated.

To assess changes in VAS scores over time, summary statistics were calculated for VAS scores on each evaluation day and changes in VAS scores from baseline to each evaluation day. A between-group *t*-test was performed to calculate two-sided 95% CIs for differences in means. A paired *t*-test was also performed for VAS scores at baseline and on each evaluation day to calculate two-sided 95% CIs for differences in means. For sleep-quality assessments, a cross-frequency table was created for the data at completion or discontinuation of treatment. Between-group comparisons by Wilcoxon rank-sum test and comparisons with baseline values by Wilcoxon signed-rank test were also performed.

Results
=======

Patients and treatment exposure
-------------------------------

Patient disposition is shown in [Figure 1](#f1-jpr-10-1953){ref-type="fig"}. Of the 184 patients enrolled, 181 were randomized: 88 to the hydromorphone group, and 93 to the oxycodone group. All of these patients received the study drugs. Of these, 72 patients in the hydromorphone group and 75 in the oxycodone group completed the study. Sixteen patients in the hydromorphone group and 18 in the oxycodone group discontinued the study. The commonest reason for study discontinuation was AEs (ten and 14 patients in the hydromorphone and oxycodone groups, respectively).

A total of 178 patients were included in the FAS. Two patients in the hydromorphone group were excluded from the FAS because they had no evaluable efficacy data after completion of study treatment, and one patient in the oxycodone group was excluded because of a major deviation. Eight and 12 patients in the hydromorphone and oxycodone groups, respectively, were excluded from the per protocol set due to protocol deviations.

Patient demographics in the FAS are shown in [Table 2](#t2-jpr-10-1953){ref-type="table"}. The mean age was 70.1 years in the hydromorphone group and 68.4 years in the oxycodone group. The proportion of patients aged 65 years or older was 77.9% (67 of 86) in the hydromorphone group and 67.4% (62 of 92) in the oxycodone group, being slightly higher in the hydromorphone group. The proportion of females in the hydromorphone group was 45.3% (39 of 86), which was slightly higher than that (33.7% \[31 of 92\]) in the oxycodone group. There was no notable difference between the two groups for other factors.

Mean (SD) VAS scores before the start of study treatment in the FAS were 53.5 (14.53) mm in the hydromorphone group and 52.1 (12.81) mm in the oxycodone group, with no notable difference between these two groups. Most patients -- 77.9% (67/86) in the hydromorphone group and 70.7% (65/92) in the oxycodone group -- completed or discontinued the study with no increase in initial dose. There was no notable between-group difference. Study-drug dose was increased twice or more for four patients in the hydromorphone group and five patients in the oxycodone group. The mean number of rescue-medication doses per day was less than one on all evaluation days for both groups, with no between-group difference.

Efficacy
--------

[Table 3](#t3-jpr-10-1953){ref-type="table"} shows the analysis of changes in VAS score in the FAS. Mean (SD) VAS scores at baseline and completion/discontinuation of treatment were 53.5 (14.53) and 23 (17.91) mm, respectively, in the hydromorphone group and 52.1 (12.81) and 23.2 (18.83) mm, respectively, in the oxycodone group, showing a decrease from baseline in both groups. Mean changes in VAS score (SD) at completion/discontinuation of treatment were similar in both groups: −30.5 (20.8) mm in the hydromorphone group and −29.1 (21.46) mm in the oxycodone group.

The between-group (hydromorphone group − oxycodone group) difference (95% CI) in least squares mean changes in VAS score from baseline to completion/discontinuation of treatment was −0.4 mm (−5.9 to 5 mm). The upper limit of the 95% CI was below 10 mm, the noninferiority limit determined at the time of planning. This verified the noninferiority of hydromorphone to oxycodone.

[Figure 2](#f2-jpr-10-1953){ref-type="fig"} shows VAS scores at baseline and on each evaluation day, as well as time-course changes (mean ± SD) in VAS score measured on each evaluation day from baseline. In both groups, mean VAS score decreased by day 2, with a trend toward increase in mean change with increasing duration of treatment. Comparison with the time-course changes in VAS score with the use of oxycodone extended-release tablets showed a similar decrease over time.

A paired *t*-test was conducted for VAS scores at baseline and on each evaluation day (days 2--8 and at completion/discontinuation of treatment). Two-sided 95% CIs calculated for differences in means are shown in [Figure 2](#f2-jpr-10-1953){ref-type="fig"}. Compared with baseline, a significant difference in VAS score was observed for all evaluation days, daily assessments on days 2--8 (*P*\<0.0001), and at completion/discontinuation of treatment (*P*\<0.0001). [Table 4](#t4-jpr-10-1953){ref-type="table"} shows sleep evaluation in the FAS. Many patients in both groups showed an improvement in sleep at completion/discontinuation of treatment compared with baseline, and there was a significant difference by Wilcoxon signed-rank test (*P*\<0.0001 for both groups).

Safety and tolerability
-----------------------

[Table 5](#t5-jpr-10-1953){ref-type="table"} shows a list of AEs with an incidence rate ≥5%. Of all the 181 randomized patients, one in the oxycodone group was excluded from the safety analysis population, owing to a major deviation. The incidence of AEs was 80.7% (71 of 88) in the hydromorphone group and 83.7% (77 of 92) in the oxycodone group, and no significant between-group difference was observed. The most common AEs (incidence rate ≥10%) were nausea, vomiting, somnolence, diarrhea, and constipation. No respiratory depression/lowered breathing was reported in either group. The incidence of severe AEs was 8% (seven of 88) in the hydromorphone group and 10.9% (ten of 92) in the oxycodone group. Severe AEs were observed in one subject (appetite loss) in the hydromorphone group and two subjects (dizziness and malaise in one patient each) in the oxycodone group ([Table 5](#t5-jpr-10-1953){ref-type="table"}).

The incidence rate of serious AEs (including death) was 12.5% (eleven of 88) in the hydromorphone group and 15.2% (14 of 92) in the oxycodone group, and there was no significant between-group difference. Of these, events considered related to study drugs were observed in four patients (hypercalcemia, appetite loss, somnolence, and vomiting in one patient each) in the hydromorphone group and six patients (ileus in two patients, and decreased level of consciousness, respiratory failure, vomiting, asthenia, and malaise in one patient each \[respiratory failure and malaise in a single patient\]) in the oxycodone group. The outcome was classified as "not resolved" for appetite loss and somnolence, occurring in one patient each, in the hydromorphone group, and for ileus, respiratory failure, and malaise, occurring in one patient each (respiratory failure and malaise in a single patient), in the oxycodone group. Other events were resolved or improved by discontinuation of study treatment or with interventions. There were no pronounced changes in laboratory values or vital signs. A 12-lead electrocardiogram showed no clinically significant QT prolongation.

Discussion
==========

This double-blind, double-dummy study compared the efficacy of hydromorphone extended-release tablets with an oxycodone extended-release tablet formulation. In order to minimize potential bias of carryover effects of opioid analgesics, we included only opioid-naïve cancer patients. The initial dose of oxycodone extended-release tablets was determined as 10 mg/day, instead of the 20 mg/day dose recommended overseas, to allow assessment of the efficacy and safety of the formulation at a lower dose. With the verified noninferiority of hydromorphone extended-release tablets to the oxycodone extended-release formulation, the efficacy of the once daily hydromorphone extended-release tablets, designed using an original technique for extended-release formulation development (\[GWATab^®^\] Gelling WAter-soluble polymer-matrix Tablet; Daiichi Sankyo Company, Limited, Tokyo, Japan),[@b13-jpr-10-1953] has been confirmed to be equivalent to that of hydromorphone extended-release tablets currently used in many countries. In addition, the magnitude of decrease in VAS score in the present study was similar to that in a preceding study (JAPICCTI-132338), which compared hydromorphone immediate-release tablets and an oxycodone immediate-release powder formulation in Japanese opioid-naïve patients with cancer pain. This suggests that we have reproduced the efficacy results from the preceding study, demonstrating hydromorphone's comparable efficacy with oxycodone in both immediate- and extended-release formulations.

Other clinical studies of oxycodone in opioid-naïve patients have reported similar baseline values of pain and similar percentages of decrease. This suggests that the efficacy results from those studies were reproduced in the present study. In addition, the most common AEs identified and their incidence rates did not greatly differ from previous reports.[@b17-jpr-10-1953]--[@b21-jpr-10-1953]

With regard to safety, incidence rates of nausea and vomiting were higher in the hydromorphone group than in the oxycodone group. However, the severity of nausea and vomiting was mild or moderate in all these patients (mild in approximately 70% of these patients). Of AEs that led to discontinuation of study treatment, nausea and/or vomiting were observed in six patients each in the hydromorphone and oxycodone groups, with similar frequency in both groups. These results suggested that there would be no problems with the tolerability of hydromorphone extended-release tablets, as in the case of the oxycodone extended-release formulation. It is known that although nausea and vomiting occur in 10%--40% of patients in the early stage of opioid treatment, most patients develop tolerance to these AEs.[@b22-jpr-10-1953]

This study has some limitations. Because it was conducted in opioid-naïve patients, the analgesic effect was investigated only in patients receiving relatively low doses. Therefore, the efficacy and safety of the hydromorphone extended-release tablets administered once daily were not confirmed in patients who were switched from other opioids and in patients requiring high-dose opioids. Further studies need to be conducted on these issues. In addition, all subjects in this study were required to take laxatives and antiemetics to allow a strict comparison between groups in incidence rates of nausea/vomiting and constipation, which are common adverse reactions to opioids.[@b23-jpr-10-1953] The impact of such prophylactic treatment on safety evaluation is unknown, and the incidence rates and severity of nausea/vomiting and constipation observed in this study cannot be compared with those in other studies that did not require prophylactic medication with antiemetics and laxatives. Another limitation of this study is that drug interactions with cancer chemotherapy, radiotherapy, and other concomitant medications and withdrawal effects for opioids were not assessed.

Conclusion
==========

We confirmed the noninferiority of hydromorphone extended-release tablets to oxycodone extended-release formulation in opioid-naïve Japanese cancer patients. The hydromorphone extended-release tablet formulation poses no significant safety concerns.

Supplementary material
======================

###### Participating institutes

1.  Hirosaki National Hospital

2.  Mito Red Cross Hospital

3.  Mito Medical Center

4.  Yuai Memorial Hospital

5.  Ibaraki Prefectural Central Hospital

6.  Tsuchiura Kyodo General Hospital

7.  Tsukuba Medical Center Hospital

8.  Tochigi Cancer Center

9.  Gunma Prefectural Cancer Center

10. Takasaki General Medical Center

11. Ageo Central General Hospital

12. National Hospital Organization Saitama National Hospital

13. National Hospital Organization Chiba Medical Center

14. Chiba Cancer Center

15. Funabashi Municipal Medical Center

16. Chiba Tokushukai Hospital

17. Kanto Central Hospital of the Mutual Aid Association of Public School Teachers

18. Tokyo Metropolitan Health and Medical Treatment Corporation Toshima Hospital

19. Kanagawa Cancer Center

20. Kawasaki Municipal Hospital

21. Shonan Kamakura General Hospital

22. Aizawa Hospital

23. Japanese Red Cross Society Suwa Hospital, Suwa Red Cross Hospital

24. Japanese Red Cross Shizuoka Hospital

25. Yaizu City Hospital

26. Shizuoka Prefectural Hospital Organization, Shizuoka General Hospital

27. Shizuoka Cancer Center

28. Aichi Cancer Center Hospital

29. Toyohashi Medical Center

30. Matsusaka City Hospital

31. Kyoto Okamoto Memorial Hospital

32. Osaka General Medical Center

33. Rinku General Medical Center

34. National Hospital Organization Kinki-Chuo Chest Medical Center

35. Saiseikai Noe Hospital

36. Sano Hospital

37. Meiwa Hospital

38. Japanese Red Cross Society Himeji Hospital

39. Institute of Biomedical Research and Innovation Hospital

40. Okayama Medical Center

41. National Hospital Organization Kure Medical Center and Chugoku Cancer Center

42. Iwakuni Clinical Center

43. Japan Community Health Care Organization, Shimonoseki Medical Center

44. Saiseikai Imabari Hospital

45. Ehime Prefectural Central Hospital

46. Saiseikai Fukuoka General Hospital

47. Japan Community Health Care Organization, Kyushu Hospital

48. Beppu Medical Center

49. Miyazaki Prefectural Miyazaki Hospital
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![Changes in VAS scores in the full-analysis set.\
**Note:** Compared with baseline VAS scores, significant changes were observed in VAS scores for assessments on days 2--8 (*P*\<0.0001) and at EOT (*P*\<0.0001).\
**Abbreviations:** VAS, visual analog scale; EOT, end of treatment (or withdrawal from treatment).](jpr-10-1953Fig2){#f2-jpr-10-1953}

###### 

Doses of investigational product and rescue medication

  Hydromorphone group   Oxycodone group   Morphine hydrochloride for rescue medication
  --------------------- ----------------- ----------------------------------------------
  4 mg/day              10 mg/day         5 mg
  6 mg/day              20 mg/day         5 mg
  8 mg/day              30 mg/day         5 mg
  12 mg/day             40 mg/day         10 mg
  18 mg/day             60 mg/day         15 mg
  24 mg/day             80 mg/day         20 mg

###### 

Baseline demographics and clinical characteristics (full-analysis set)

  Characteristics                              Hydromorphone group (n=86)   Oxycodone group (n=92)   Total (n=178)
  -------------------------------------------- ---------------------------- ------------------------ ---------------
  **Age (years)**                                                                                    
  Mean                                         70.1                         68.4                     69.2
  SD                                           10.19                        9.17                     9.69
  **Sex, n (%)**                                                                                     
  Male                                         47 (54.7)                    61 (66.3)                108 (60.7)
  Female                                       39 (45.3)                    31 (33.7)                70 (39.3)
  **Body weight (kg)**                                                                               
  Mean                                         51.85                        54.65                    53.3
  SD                                           11.069                       12.469                   11.863
  **Body-mass index (kg/m^2^), n (%)**                                                               
  \<25 kg/m^2^                                 72 (83.7)                    83 (90.2)                155 (87.1)
  ≥25 kg/m^2^                                  14 (16.3)                    9 (9.8)                  23 (12.9)
  **Underlying disease (tumor type), n (%)**                                                         
  Lung                                         31 (36)                      25 (27.2)                56 (31.5)
  Breast                                       6 (7)                        6 (6.5)                  12 (6.7)
  Gastrointestinal                             26 (30.2)                    39 (42.4)                65 (36.5)
  Hepatic--biliary--pancreatic                 12 (14)                      15 (16.3)                27 (15.2)
  Urogenital                                   10 (11.6)                    6 (6.5)                  16 (9)
  Others                                       1 (1.2)                      1 (1.1)                  2 (1.1)
  **ECOG performance status, n (%)**                                                                 
  0                                            17 (19.8)                    21 (22.8)                38 (21.3)
  1                                            41 (47.7)                    50 (54.3)                91 (51.1)
  2                                            21 (24.4)                    14 (15.2)                35 (19.7)
  3                                            7 (8.1)                      7 (7.6)                  14 (7.9)
  4                                            0                            0                        0
  **Visual analog scale (mm)**                                                                       
  Mean                                         53.5                         52.1                     52.8
  SD                                           14.53                        12.81                    13.65

**Abbreviation:** ECOG, Eastern Cooperative Oncology Group.

###### 

Changes in visual analog-scale scores (full-analysis set)

  Parameters                                                      Hydromorphone group, n=86   Oxycodone group, n=92
  --------------------------------------------------------------- --------------------------- -----------------------
  **Baseline, mm**                                                                            
  Mean                                                            53.5                        52.1
  SD                                                              14.53                       12.81
  Minimum                                                         36                          35
  Median                                                          49                          49
  Maximum                                                         97                          95
  **At completion/discontinuation of treatment, mm**                                          
  Mean                                                            23                          23.2
  SD                                                              17.91                       18.83
  Minimum                                                         0                           0
  Median                                                          19                          20
  Maximum                                                         66                          90
  **Change, mm**                                                                              
  Mean                                                            −30.5                       −29.1
  SD                                                              20.8                        21.46
  Minimum                                                         −87                         −73
  Median                                                          −31.5                       −31
  Maximum                                                         19                          42
  Least squares mean[a](#tfn2-jpr-10-1953){ref-type="table-fn"}   −30                         −29.6
  Difference[a](#tfn2-jpr-10-1953){ref-type="table-fn"}           −0.4                        
  95% CI                                                          −5.9 to 5                   
  *P*-value                                                       0.8732                      

**Notes:**

Hydromorphone group -- oxycodone group. Analysis of covariance (explanatory variable: baseline visual analog-scale score, groups).

###### 

Sleep evaluation (cross-frequency table, full-analysis set)

  Group                            Baseline                                       At completion/discontinuation of treatment                                       
  -------------------------------- ---------------------------------------------- -------------------------------------------- ----------- ----------- ----------- ---------
  **Hydromorphone group (n=86)**   0\. Very unsatisfactory/did not sleep at all   0                                            2           6           4           12 (14)
  1\. Markedly unsatisfactory      0                                              5                                            9           6           20 (23.3)   
  2\. Slightly unsatisfactory      1                                              6                                            21          14          42 (48.8)   
  3\. Satisfactory                 0                                              1                                            6           5           12 (14)     
  Total, n (%)                     1 (1.2)                                        14 (16.3)                                    42 (48.8)   29 (33.7)   86          
  **Oxycodone group (n=92)**       0\. Very unsatisfactory/did not sleep at all   0                                            3           2           1           6 (6.5)
  1\. Markedly unsatisfactory      1                                              9                                            16          7           33 (35.9)   
  2\. Slightly unsatisfactory      1                                              6                                            17          21          45 (48.9)   
  3\. Satisfactory                 0                                              0                                            0           8           8 (8.7)     
  Total, n (%)                     2 (2.2)                                        18 (19.6)                                    35 (38.0)   37 (40.2)   92          

**Notes:** Compared with baseline evaluations, change in sleep in both groups was significantly different (*P*\<0.0001) at end of treatment (Wilcoxon signed-rank test). However, there were no significant (*P*=0.7683) between-group differences in sleep evaluations (Wilcoxon rank sum test).

###### 

List of adverse events with incidence of ≥5% (safety analysis set)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Preferred term[a](#tfn4-jpr-10-1953){ref-type="table-fn"}        Hydromorphone group (n=88)\   Oxycodone group (n=92)[\*](#tfn5-jpr-10-1953){ref-type="table-fn"}\   Total (n=180\
                                                                   n (%)                         n (%)                                                                 n (%)
  ---------------------------------------------------------------- ----------------------------- --------------------------------------------------------------------- ---------------
  Patients with adverse event/s                                    71(80.7)                      77 (83.7)                                                             148 (82.2)

  Nausea                                                           36 (40.9)                     21 (22.8)                                                             57 (31.7)

  Vomiting                                                         32 (36.4)                     16 (17.4)                                                             48 (26.7)

  Somnolence                                                       23 (26.1)                     18 (19.6)                                                             41 (22.8)

  Diarrhea[\#](#tfn6-jpr-10-1953){ref-type="table-fn"} 16 (18.2)                                 17 (18.5)                                                             33 (18.3)

  Constipation                                                     11 (12.5)                     14 (15.2)                                                             25 (13.9)

  Fever                                                            7 (8)                         5 (5.4)                                                               12 (6.7)

  Dizziness                                                        6 (6.8)                       5 (5.4)                                                               11 (6.1)

  Appetite loss                                                    7 (8)                         3 (3.3)                                                               10 (5.6)

  Malaise                                                          3 (3.4)                       6 (6.5)                                                               9 (5)
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

As per MedDRA (Medical Dictionary for Regulatory Activities) version 18.1;

major protocol deviation in one patient;

the reason for high diarrhea incidence was not clear and may have been the use of prophylactic laxatives.
